Arix Bioscience
VC Fund
London, United Kingdom
Arix Bioscience is a global healthcare and life science company that drives value in private and public companies through operational and strategic direction as well as patient capital Their extensive experience in academic science, clinical and commercial strategy, company operations, mergers and acquisitions, venture capital and corporate financeputs them in an especially strong position to build and support a wide range of businesses and technologies.Arix Bioscience has privileged agreements with leading universities in the UK, Europe and Australia, providing direct access to innovative new technologies. They also have access to a broad range of research projects from US academic institutions.
- Total investments:
- 33
- Last investment:
- Lead investor:
- 42%
Last updated:
For AI agents: llms.txt
Industries Arix Bioscience invests in
Stages Arix Bioscience invests in
Countries Arix Bioscience invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $20M–$58M
- Series B
- $45M–$137M
- Series C
- $53M–$153M
Investment Focus
Industry
- Biotechnology 20 (61%)
- Health Care 10 (30%)
- Therapeutics 8 (24%)
- Pharmaceutical 8 (24%)
- Medical 7 (21%)
Stage
- Series B 11 (33%)
- Series A 8 (24%)
- Series C 5 (15%)
- Post-IPO Equity 3 (9%)
- Seed 1 (3%)
Country
- United States 12 (36%)
- France 2 (6%)
- Israel 2 (6%)
- United Kingdom 2 (6%)
- Canada 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Daniel O'Connell
Investment Manager
|
Investment Manager | Total investments: 3 | Find email | |
James Rawlingson
Chief Financial Officer
|
Chief Financial Officer | Total investments: 0 | Find email | |
Jonathan Tobin
Managing Director
|
Managing Director | Total investments: 10 | Find email | |
Chris Evans
Deputy Chairman
|
Deputy Chairman | Total investments: 0 | Find email | |
Chris Evans
Deputy Chairman
|
Deputy Chairman | Total investments: 0 | Find email | |
| See all 7 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Evommune
|
Evommune is taking a tissue-based approach to insights and accelerating the development of transformative medicines for inflammatory diseases. Evommune creates novel strategies to treat inflammatory disorders by developing treatments that address symptoms while also halting disease progression. Evommune's pipeline contains initiatives aimed atcombating highly prevalent inflammatory illnesses. Its mission is to drive real advancements for patients suffering from these diseases, with all of its programs designed to produce best-in-class profiles. | $50M / Series B / Apr 26, 2023 | |
Harpoon Therapeutics
|
Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, orantigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon's first drug candidate, HPN424, is currently in Phase 1 clinical trial as a treatment for prostate cancer. | $25M / Post-IPO Equity / Mar 27, 2023 | |
Ensoma
|
Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious™ vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As aresult, Ensoma’s therapies can be delivered as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited. | $85M / Series B / Jan 05, 2023 | |
Disc Medicine
|
Disc Medicine is led by an experienced team of scientists and industry experts, and supported by a panel of advisors with a strong track record of discovering and developing new and innovative therapies. Disc Medicine was founded by Atlas Venture and Brian MacDonald, with Novo Ventures and Access Biotechnology joining as additional investors. | $53.5M / Post-IPO Equity / Dec 30, 2022 | |
|
Disc Medicine
|
Disc Medicine is led by an experienced team of scientists and industry experts, and supported by a panel of advisors with a strong track record of discovering and developing new and innovative therapies. Disc Medicine was founded by Atlas Venture and Brian MacDonald, with Novo Ventures and Access Biotechnology joining as additional investors. | $53.5M / Aug 10, 2022 | |
|
Sorriso Pharmaceuticals
|
Sorriso Pharmaceuticals is a biotechnology company advancing a pipeline of disease-modifying antibodies for the treatment of inflammatory disease, including Crohn’s disease and ulcerative colitis. The Sorriso platform generates potent antibodies that can be delivered orally and are designed to maintain activity throughout the intestinal system.The company was founded in 2020 and is based in San Diego, California. | $31M / Series A / Dec 22, 2021 | |
Depixus
|
Depixus are pioneering the development of MAGNA, a novel genetic analysis technology for decoding the dynamic genome. | $34.5M / Series A / Dec 15, 2021 | |
|
Disc Medicine
|
Disc Medicine is led by an experienced team of scientists and industry experts, and supported by a panel of advisors with a strong track record of discovering and developing new and innovative therapies. Disc Medicine was founded by Atlas Venture and Brian MacDonald, with Novo Ventures and Access Biotechnology joining as additional investors. | $90M / Series B / Sep 02, 2021 | |
|
Disc Medicine
|
Disc Medicine is led by an experienced team of scientists and industry experts, and supported by a panel of advisors with a strong track record of discovering and developing new and innovative therapies. Disc Medicine was founded by Atlas Venture and Brian MacDonald, with Novo Ventures and Access Biotechnology joining as additional investors. | $90M / Post-IPO Equity / Sep 02, 2021 | |
Artios Pharma
|
Artios is an independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. Artios is building a pipeline of next-generation DDR programs, including through a uniquepartnership with Cancer Research Technology (CRT), the development and commercialization arm of Cancer Research UK (CRUK), and with leading DNA repair researchers worldwide. The Company’s investors include SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Institute in Cambridge, UK. | $152.7M / Series C / Jul 27, 2021 | |
| See all 33 investments → | |||
Co-Investors
OrbiMed
11 deals together
Lundbeckfonden Ventures
7 deals together
Atlas Venture
6 deals together
Janus Henderson Investors
6 deals together
Rock Springs Capital
6 deals together
Novo Holdings
5 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Arix Bioscience invest in?
Arix Bioscience invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series A stage. Most of the 33 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Arix Bioscience's check size?
Arix Bioscience typically joins rounds of $20M–$58M at Series A, $45M–$137M at Series B and $53M–$153M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Arix Bioscience participates in.
How do I contact Arix Bioscience?
Public channels for Arix Bioscience include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Arix Bioscience?
The team at Arix Bioscience includes Daniel O'Connell (Investment Manager), James Rawlingson (Chief Financial Officer) and Jonathan Tobin (Managing Director), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
